BiondVax completes patient enrolment in phase 2b trial of M-001 universal flu vaccine candidate

The trial, conducted in collaboration with the EU-sponsored UNISEC consortium, is designed to evaluate the safety and immunogenicity of M-001 when used ahead of an avian influenza vaccine.

Among other goals the study aims to show the dose sparing potential of M-001 when given prior to avian vaccine, a highly desirable feature in a pandemic scenario, when existing stockpiles of vaccine may be insufficient.

BiondVax chief scientist Tamar Ben-Yedidia said: "This important milestone, along with the NIH-sponsored Phase 2 trial in the USA, keeps BiondVax on track to be Phase 3 ready by 2017/18.

"We are excited to be one step closer to bringing our multi-strain and multi-season vaccine against seasonal and pandemic flu to the market."

Prof. Dr. Eelko Hak, UNISEC clinical trial program work package leader, said: "This important clinical trial is a major contribution to the mission of the European UNISEC consortium to learn more about the potential of these promising broadly reactive new vaccines."